Rapport Therapeutics, Inc./$RAPP
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Ticker
$RAPP
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
69
ISIN
US75383L1026
Website
RAPP Metrics
BasicAdvanced
$439M
-
-$2.74
-
-
Price and volume
Market cap
$439M
52-week high
$14.78
52-week low
$6.43
Average daily volume
203K
Financial strength
Current ratio
31.01
Quick ratio
30.415
Long term debt to equity
2.391
Total debt to equity
2.744
Profitability
EBITDA (TTM)
-92.138
Management effectiveness
Return on assets (TTM)
-22.89%
Return on equity (TTM)
-33.14%
Valuation
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-5.062
Free cash flow yield (TTM)
-19.75%
Free cash flow per share (TTM)
-237.83%
Growth
Earnings per share change (TTM)
-91.03%
Bulls say / Bears say
Rapport Therapeutics' lead investigational drug, RAP-219, is progressing through multiple Phase 2a trials targeting refractory focal epilepsy and bipolar mania, with topline results expected in Q3 2025 and H1 2027, respectively, indicating potential for significant clinical advancements. (globenewswire.com)
The company maintains a strong financial position with $285.4 million in cash, cash equivalents, and short-term investments as of March 31, 2025, expected to fund operations through the end of 2026, providing a solid foundation for ongoing research and development. (globenewswire.com)
Analysts at JMP Securities initiated coverage of Rapport Therapeutics with a 'Market Outperform' rating and a price target of $28.00, suggesting confidence in the company's growth prospects and potential stock appreciation. (nasdaq.com)
Rapport Therapeutics reported a net loss of $24.1 million for Q1 2025, an increase from $22.7 million in the prior year period, reflecting rising operational expenses that may impact financial stability. (globenewswire.com)
The FDA has placed a clinical hold on the IND for RAP-219 in diabetic peripheral neuropathic pain, requesting additional information, which could delay development timelines and affect investor confidence. (tradingview.com)
Insider buying activity, such as the CFO purchasing 9,900 shares at $10.10 per share, may indicate confidence but also suggests the stock is undervalued, potentially reflecting market skepticism about the company's near-term prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RAPP News
AllArticlesVideos
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
MarketBeat·3 weeks ago
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
GlobeNewsWire·1 month ago
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rapport Therapeutics, Inc. stock?
Rapport Therapeutics, Inc. (RAPP) has a market cap of $439M as of July 04, 2025.
What is the P/E ratio for Rapport Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Rapport Therapeutics, Inc. (RAPP) stock is 0 as of July 04, 2025.
Does Rapport Therapeutics, Inc. stock pay dividends?
No, Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Rapport Therapeutics, Inc. dividend payment date?
Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders.
What is the beta indicator for Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc. (RAPP) does not currently have a Beta indicator.